Shopping Cart
- Remove All
- Your shopping cart is currently empty
OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $479 | In Stock | |
10 mg | $653 | In Stock | |
25 mg | $990 | In Stock | |
50 mg | $1,330 | In Stock | |
100 mg | $1,750 | In Stock | |
200 mg | $2,370 | In Stock | |
1 mL x 10 mM (in DMSO) | $597 | In Stock |
Description | OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively. |
Targets&IC50 | α2A-adrenoceptor:2040 nM (ki), α2C-adrenoceptor:55 nM (ki), α2B-adrenoceptor:285 nM (ki) |
In vitro | OPC-28326 augments microvessel growth and improves endothelial tube formation. OPC-28326 dose-dependently induces phosphorylation of eNOS and Akt without affecting total amounts of eNOS and Akt in HAECs[1]. |
In vivo | OPC-28326 improves blood flow recovery in murine hindlimb ischemia and increases the number of capillaries in the ischemic leg[1]. In rats, intravenous administration of OPC-28326 (3 - 30 mg/kg) and yohimbine (0.3 - 3 mg/kg) results in a dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920 without affecting the mydriasis[2]. |
Molecular Weight | 421.58 |
Formula | C26H35N3O2 |
Cas No. | 167626-17-7 |
Smiles | C(=O)(C1=CC(C)=C(NC(CC)=O)C(C)=C1)N2CCC(N(CCC3=CC=CC=C3)C)CC2 |
Relative Density. | 1.13 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 4.22 mg/mL (10.01 mM), Sonication is recommended. ![]() | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.